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Abstract 
This paper considers the recent global concern of psychoactive substance use alongside 
New Zealand’s corresponding endeavour to regulate such substances under the 
Psychoactive Substances Act 2013. It establishes that psychoactive substances pose a risk 
of harm to individual consumers and to society in general. In light of this risk, it 
considers whether such harm justifies state intervention, whereby the autonomy of 
individuals would be limited for the safety of those individuals and the benefit of society. 
The theories of legal and political philosophers, including Immanuel Kant and John 
Stuart Mill, are considered to determine the philosophical basis for such regulation. This 
paper finds that such state paternalism, as found in the Psychoactive Substances Act, is 
justified. Having concluded that the Misuse of Drugs Act 1975 was insufficient to 
minimise the risk of harm caused by such substances, it argues in favour of the regulatory 
scheme established under the Psychoactive Substances Act. It concludes that the 
Psychoactive Substances Act is a revolutionary and innovative measure that will 
successfully minimise the harm caused, to individuals and society in general, by such 
substances.  
 
 
Word length 
The text of this paper (excluding abstract, table of contents, footnotes and bibliography) 
comprises approximately 15,032 words. 
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I   Introduction  
 
The Psychoactive Substances [Act] ends this dangerous game of cat and mouse by banning 
the import, the manufacture, the sale, the supply, and the possession of psychoactive 
substances. It reverses the onus of proof by making all psychoactive substances illegal, unless 
the industry can prove their products are low risk.1 
 
Prior to the enactment of the Psychoactive Substances Act 2013 (PSA), the Misuse of 
Drugs Act 1975 (MoDA) allowed the government to classify and control psychoactive 
substances in New Zealand. Traditionally, the MoDA prohibited illicit substances 
recognised, by the New Zealand Government and international organisations, as those 
which pose a risk of harm to individual consumers and society.2 The conventionally 
narrow scope of the MoDA had previously allowed new psychoactive substances to 
infiltrate society and cause harm to individual consumers. These new psychoactive 
substances had, up until 17 July 2013, remained mostly unregulated. “This lack of 
regulation [meant a] lack of safety measures and controls.”3 Psychoactive substances 
were sold in New Zealand with very little, if any, consideration of their chemical 
composition, any associated health risks, or the age of the consumer.4 As a result, the Hon 
Peter Dunne MP put forward the PSA in an attempt to control the manufacture, 
importation, and sale of these substances in New Zealand.5 
 
Part II clarifies the purpose and scope of this research paper on psychoactive substances. 
Part III then analyses the terminology used to describe psychoactive substances and 
products. Part IV identifies and discusses the international obligations that impose a duty 
on New Zealand to contribute towards reducing drug-related harm. Part V briefly 
identifies a number of harms and social problems that may result from the use of 
psychoactive substances by individuals. Part VI then provides an in-depth consideration 
of the applicability of the theories of state paternalism, individual autonomy, and 
utilitarianism. These theories are considered alongside the wider interests of society to 
determine whether regulation and, under some circumstances, prohibition of psychoactive 
  
1   (9 April 2013) 689 NZPD 9133. 
2   Misuse of Drugs Act 1975, s 3A.  
3   New Zealand Drug Foundation “Submission to the Health Committee on the Psychoactive                       
  Substances Bill 2013” at [2]. 
4   Brook Sabin “Dairies becoming ‘drug dealers’, Parliament hears” 3 News (online ed, New  
  Zealand, 8 May 2013) <http://www.3news.co.nz>. 
5   United Future “Dunne: legal highs regime costs and penalties announced” (press release, 10  
  October 2012). 
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substances can ever be justified. Part VII analyses the previous method of controlling 
psychoactive substances that were not scheduled as class A, B, or C drugs under the 
MoDA. It then concludes that the previous legislative procedure under the MoDA was 
insufficient to address the harms posed by unregulated and harmful psychoactive 
substances. 
 
This paper then analyses, in Part VIII, the PSA to determine whether the new regulatory 
scheme will be sufficient to address the current problem caused by psychoactive 
substances in New Zealand. Having established that the PSA will allow substances that 
only pose a low risk of harm to be manufactured, imported, and sold, this paper asserts 
that the PSA will impose the bare minimum level of restrictions upon a person’s 
individual autonomy. It is concluded that the recent reformation of the law on 
psychoactive substances was necessary and, for the most part, is sufficient to address the 
harms caused by such substances. 
 
II The Scope of This Paper  
 
This paper is primarily concerned with psychoactive substances that are not currently 
controlled under the MoDA as class A, B, or C drugs.6 These substances, often known to 
society as legal highs7 or designer drugs,8 have the potential to mimic controlled 
substances and produce adverse effects. This paper addresses the potential harms caused 
by psychoactive substances and considers whether the PSA provides a suitable 
mechanism for controlling such substances in New Zealand. This paper also briefly 
considers substances that are controlled under the MoDA, as class A, B or C drugs,9 to 
demonstrate the harm that may be caused by dangerous psychoactive substances in 
general. 
 
III What Is Meant by Psychoactive? 
 
The term “psychoactive” has been defined as that which is capable of “affecting the 
mind”.10 This definition is exceptionally broad and requires further analysis to determine 
  
6   Misuse of Drugs Act, schs 1-3.   
7   United Nations Office on Drugs and Crime 2013 World Drug Report Sales No. E.13.XI.6 (2013)  
  at 63. 
8   At 61.  
9   Misuse of Drugs Act, schs 1-3.  
10   Ray Corsini The Dictionary of Psychology (1st ed, Brunner Routledge, New York, 2002) at 778. 
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what is meant by the terms “psychoactive substance” and “psychoactive product”. The 
term “psychoactive” has been recognised as a synonym for “psychotropic”.11 
“Psychotropic drugs” are drugs that “produce mind-altering effects that may appear to be 
psychosis”.12 A “drug” is “a medicine or other substance which has a physiological effect 
when ingested or otherwise introduced into the body”.13 “Psychosis” is defined as: 14 
 
…a severe mental disorder of organic, psychological, functional cause, or the 
combination, that leads to bizarre mental states and behaviour. Signs may include 
confusion, delusions, hallucinations, incoherence, phobias, mood swings, mutism, [and] 
violence. 
A The Meaning of Psychoactive Substance 
 
The PSA, covered in further detail in Part VIII, provides a definition of the term 
“psychoactive substance”. Section 9(2)(b) states that a psychoactive substance is “a 
substance, mixture, preparation, article, device, or thing that is capable of inducing a 
psychoactive effect (by any means) in an individual who uses the psychoactive 
substance.”15 Consequently, for “a substance, mixture, preparation, article, device or 
thing” to be regarded as a psychoactive substance, it must produce a “psychoactive 
effect”. The term “psychoactive effect” is defined under the PSA as meaning “the effect 
of the substance on the individual’s mind”.16 
 
Ultimately, the Health Select Committee suggested that a narrow definition of the term 
“psychoactive substance” should be excluded from the PSA for two reasons. Firstly, 
although there was a risk that garden plants and low risk herbal products may be brought 
under the ambit of the PSA, a narrow definition should be excluded to “avoid leaving 
loopholes”.17  Secondly, the PSA also grants the Governor-General the ability to declare 
substances not to be psychoactive for the purposes of the Act.18 It is expected that this 
  
11   At 778. 
12   Graham Gooch and Michael Williams “A Dictionary of Law Enforcement” (2007) Oxford  
 Reference <http://www.oxfordreference.com>. 
13   Oxford Dictionaries “Oxford English Dictionary” (2013) Oxford Dictionaries 
<https://www.oxforddictionaries.com>. 
14   Ray Corsini, above n 10, at 788. 
15   Psychoactive Substances Act 2013, s 9(2)(b). 
16   Section 8.  
17   Psychoactive Substances Bill 2013 (100-2) (commentary) at 2.  
18   At 2. 
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will alleviate most concerns about minor psychoactive substances being captured under 
the PSA.19  
 
Furthermore, s 9(3) offers some protection to substances that are regulated elsewhere.20 
These excluded substances include controlled drugs, medicines, food, herbal remedies, 
dietary supplements, alcohol, tobacco, and other substances declared by the Governor-
General not to be psychoactive substances for the purposes of the Act.21 It is necessary to 
exclude such substances from the ambit of the PSA to prevent an unclear system where 
one substance may be covered under different, and potentially inconsistent, pieces of 
legislation. 
B The Meaning of Psychoactive Product 
 
Section 8 of the PSA determines that a “psychoactive product or product means a 
finished product packaged and ready for retail sale that is a psychoactive substance or 
contains 1 or more psychoactive substances”.22 As a result, any product ready for retail 
sale, which contains a psychoactive substance, will have to adhere to the provisions under 
the PSA before it can be sold to consumers.23  
 
IV International Obligations  
 
The issue of the manufacture, importation, sale, and use of illicit drugs and psychoactive 
substances is not limited to New Zealand. “New Zealand has ratified three United 
Nations drug conventions that require New Zealand to make the cultivation, distribution, 
and possession of drugs listed in the conventions … a criminal offence.”24 To assist 
nation states with meeting their obligations, the International Narcotics Control Board25 
  
19  (9 July 2013) 692 NZPD 11777. 
20  Psychoactive Substances Act, s 9(3). 
21  Section 9(3). 
22  Section 8. 
23  Section 33.  
24  Ministry of Health Regulatory Impact Statement: New Regulatory Regime for Psychoactive  
  Substances (1 July 2012) at 19; See generally - Single Convention on Narcotic Drugs of 1961 529 
UNTS 151 (opened for signature 24 January 1961, entered into force 13 December 1964); United 
Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 1582 
UNTS 95 (opened for signature 20 December 1988, entered into force 11 November 1990). 
Convention on Psychotropic Substances 1971 1019 UNTS 175 (opened for signature 11 January 
1971, entered into force 16 August 1976).  
25   Single Convention on Narcotic Drugs of 1961, art 9.  
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has published the names of illicit substances that must be controlled under domestic 
law.26 New Zealand has previously met these obligations by prohibiting the listed 
substances under the MoDA.27 However, it has now become uncertain as to whether this 
method of prohibition is sufficient to confront the new global problem caused by harmful 
psychoactive substances. 
 
The United Nations Office on Drugs and Crime has recognised:28  
 
… scheduling or controlling a substance is a lengthy - and costly - process, especially as 
it is the authorities who bear the onus of proof. Additionally, controlling an ever-larger 
number of substances, affecting police, customs, forensic laboratories, import/export 
authorities and the health authorities, among others, may stretch some Member States 
beyond their capacities. 
 
Prior to the PSA, the onus was on the state to prove that a psychoactive substance posed a 
risk of harm. Consequently, the responsibility of funding research on psychoactive 
substances to determine their level of risk also rested on the state.29  
 
During the second reading of the PSA, Mr Dunne stated:30 
 
…if this legislation is, as I believe it will be, successful, then we can expect to see that 
model picked up and implemented right around the world, because this issue is not one 
just for this country; it is one that is affecting every jurisdiction. 
 
It is apparent that the use of harmful psychoactive substances is a global issue. Mr Dunne 
also informed Parliament that, during the 2013 United Nations Office on Drugs and 
  
26  International Narcotics Control Board List of Psychotropic Substances under International  
Control: In accordance with the Convention on Psychotropic Substances of 1971 (24th ed, May 
2010); International Narcotics Control Board Red List: List of Precursors and Chemicals 
Frequently used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under 
International Control: In accordance with the United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances 1988 (13th ed, January 2012); International 
Narcotics Control Board Yellow List: List of Narcotic Drugs under International Control: In 
accordance with the Single Convention on Narcotic Drugs 1961 (51st ed, December 2012). 
27   Misuse of Drugs Act 1975, s 3A; Schedules 1-5. 
28   United Nations Office on Drugs and Crime, above n 7, at xiii. 
29   (2 July 2013) 691 NZPD 11577.  
30   (27 June 2013) 691 NZPD 11395. 
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Crime meeting, other nations were considering New Zealand’s then proposed legislative 
change with great interest.31  
  
Furthermore, in 2013, the Commission on Narcotic Drugs passed a resolution that 
requires all member states to collect and share information about new psychoactive 
substances.32 The PSA will assist New Zealand with meeting this obligation as it permits 
the sharing of information, gathered for the purposes of regulation, with the World Health 
Organization and fellow World Trade Organization countries.33 This will allow New 
Zealand to provide information, gathered from preclinical and clinical trials paid for by 
manufacturers and importers of psychoactive substances, to other member states. 
 
V  Do Psychoactive Substances Pose a Risk of Harm?  
 
Having established that New Zealand is under an obligation to reduce drug-related harm, 
this paper now determines whether psychoactive substances are able to cause harm to 
individual consumers and society in general. The New Zealand Drug Foundation (NZDF) 
has a national focus of minimising drug related harm.34 In its submission to the Health 
Select Committee on the PSA, the NZDF outlined a selection of harms that may be 
caused by psychoactive substances:35 
 
…harms to individuals and families include injury, disease, social, personal and financial 
problems and a reduced quality of life. Harms to societies include unsafe communities, 
increased need for law enforcement, and high health and economic costs.  
 
The NZDF also submitted that recent reports have indicated psychoactive substances may 
have severe detrimental effects on the physiological and psychological health of 
individual consumers. “[These] reported harms are wide ranging and include agitation 
and paranoia through to psychosis, kidney-failure, limb loss and even death”.36  
 
  
31  (9 April 2013), 689 NZPD 9134. 
32  The Commission on Narcotic Drugs Promoting the sharing of expertise in and knowledge on  
forensic drug profiling GA Res 56/5, E/2013/28 (2013). 
33  Psychoactive Substances Act, s 36(3)(a).  
34  New Zealand Drug Foundation, above n 3, at [8]. 
35  At [8]. 
36  At [2]. 
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A Case Study: Massey University Study on Legal Party Pill use in New Zealand 
 
“[This] survey consisted of a random national household sample of 2,010 people aged 13-
45 years old”.37 Out of the results obtained, it was reported that 50.4 per cent experienced 
trouble sleeping, 18.4 per cent experienced a loss of energy, 15.6 per cent experienced 
strange thoughts, 14.8 per cent experienced mood swings and 8.4 per cent experienced 
paranoia. The survey also recorded significant physical harms caused by the use of legal 
party pills. The physical problems most often experienced from the use of legal party pills 
included “poor appetite, hot/cold flushes, heavy sweating, stomach pains/nausea, 
headaches, and tremors and shakes”.38 The results from this study demonstrate that the 
harms caused by psychoactive substances are wide ranging and have the potential to be 
different for each individual consumer. 
B Case Study: Gamma-hydroxybutyrate (GHB) 
 
…between 2000, when [GHB] was assessed by the EACD [Expert Advisory Committee on 
Drugs] and its eventual scheduling in the Act in 2002, Auckland Hospital reported over thirty 
admissions and one death associated with GHB misuse.39   
 
Research published in the American Journal of Emergency Medicine in 2011 determined 
that out of the “226 deaths included 213 had cardiorespiratory arrest and 13 had fatal 
accidents”.40 The study also provided an example of a label found on a psychoactive 
product that contained the psychoactive substance GHB:41  
 
Excessive doses may result in sweating, muscle spasms, vomiting, bedwetting, and 
diarrhoea. Unless drugs or alcohol have been taken with ZEN, the only treatment 
necessary is to SLEEP IT OFF! A call for help may result in uninformed emergency 
medical personnel using expensive, unnecessary, and potentially dangerous methods of 
arousal. 
  
37  C Wilkins and others Legal party pill use in New Zealand: Prevalence of use, availability, health  
harms and ‘gateway effects’ of benzylpiperazine (BZP) and trifluoromethylphenylpiperazine 
(TFMPP) (Centre for Social and Health Outcomes Research and Evaluation, Auckland, 2006) at 5. 
38  At  32. 
39  Ministry of Health Regulatory Impact Statement, above n 24, at 23; See also - Expert Advisory  
Committee on Drugs The Expert Advisory Committee on Drugs’ (EACD) advice on: Gamma-
Hydroxybutyric Acid and Related Substances (‘Fantasy’) (December 2001).  
40  Deborah L. Zvosec and Others “Case Series of 226 y-hydroxybutyrate – Associated Deaths:  
Lethal Toxicity and Trauma” (2011) 29(3) American Journal of Emergency Medicine 319 at 319.  
41  At 320.  
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This dangerous fiction created by the psychoactive substances industry is of particular 
concern when one considers the findings of the study in relation to bystanders:42 
 
… of 102 cases with known symptoms before death, 30 were victims left “sleeping” or 
“snoring” by witnesses and later found in arrest or dead. Seventy-two others had 
witnessed adverse effects (agitation, vomiting, seizures, loss of consciousness); for 66 of 
these, activation of emergency medical services was delayed until the victim was found 
in arrest or dead.  
 
These statistics demonstrate that there is often an unhealthy and undesirable competition 
between the psychoactive substances industry and governments. Manufacturers and 
importers have an interest in encouraging consumers to use their products, whereas the 
government of a nation maintains an interest in keeping individuals and society safe from 
harm.43 
C Case Study: The “Miami Zombie” 
 
In May 2012, Rudy Eugene, who was presumed to be under the influence of psychoactive 
substances, was shot by Miami police after he chewed off 75 per cent of a man’s face.44 
The toxicology report held that no psychoactive substances were detected in his system at 
the time of his death; however, the adequacy of such testing regimes is uncertain. After 
the toxicology report was released, Dr Barry Logan acknowledged that “there are 
hundreds of bath salt compounds out there, but toxicologists can only test for 40”.45 Even 
after the report came back clear, experts reported that “there is no question Eugene’s 
behaviour was drug-induced – and not by marijuana. But [it is] hard to prove because 
even the most sophisticated labs cannot test for every compound”.46 
 
Since their creation, this particular class of psychoactive substances has been proven to 
inflict extremely detrimental effects on individual consumers:47 
  
42  At 323.  
43  Peter Dunne “Dunne: legal highs regime costs and penalties announced” (press release, 10  
October 2012).    
44  Andrew Moran “Bath Salts – Inside the rise of latest drug to capture notoriety” (30 May 2012)  
Digital Journal <http://www.digitaljournal.com>. 
45  Susannah Bryan “Even experts question claim that Rudy Eugene was not on bath salts” (6 July  
2012) Sun Senteniel <http://www.sun-senteniel.com>. 
46  Susannah Bryan, above n 45.  
47  Andrew Moran, above n 44.  
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Bath salts are composed of MDPV, mephedrone and pyrovalerone and because of its 
chemical composition it can establish short- and long-term effects for the users. 
Individuals who consume bath salts desire a euphoric feeling that can also increase 
energy, arousal, sociability and motivation. However, the actual results are frightening as 
bath salts can lead to suicidal thoughts, paranoia, psychotic delusions and violent 
behaviour. 
 
The incident involving Mr Eugene occurred months after one of the most commonly used 
compounds in the manufacturing of bath salts, Methylenedioxypyrovalerone (MDPV), 
was classified as dangerous by the American National Institute on Drug Abuse.48 In New 
Zealand, MDPV is classified as an illegal substance because it is an analogue substance 
of the Class B controlled drug Pyrovalerone.49   
 
Having established that psychoactive substances have the ability to cause great harm to 
individuals and society, it would be unreasonable to allow psychoactive substances to be 
manufactured, imported, or sold in a manner that is unsafe. Instead, this paper concludes 
that it is necessary to consider what safeguards could, and should, be implemented to 
reduce this risk of harm.  
 
VI Can State Regulation of Psychoactive Substances be justified? 
 
Various legal and political philosophers have considered whether the state is justified in 
intervening with the actions of an individual. Three influential and compelling theories 
used to answer this question include the concept of paternalism by the state, the notion of 
individual autonomy, and the consequentialist theory of utilitarianism. 
A State Paternalism 
 
The concept of paternalism can be divided into two categories. Pure paternalism occurs 
when “the class of persons whose freedom is restricted is identical with the class of 
persons whose benefit is to be promoted by such restrictions”.50 Impure paternalism 
  
48  Nora Volkow “Bath Salts: Emerging and Dangerous Products” (February 2011) National Institute  
on Drug Abuse <http://www.drugabuse.gov>. 
49  Misuse of Drugs Act, sch 1(2)(1); Nicholas Jones “Police warn on tainted E pills” The New  
Zealand Herald (Online ed, New Zealand, 28 September 2011) <http://www.nzherald.co.nz>. 
50  Gerald Dworkin “Paternalism” (1970) in J Feinberg and H Gross (ed) Philosophy of Law, 4th ed,  
(1991) 258 at 260.  
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occurs when the class of persons whose freedom is restricted is not identical with the 
class of persons whose benefit is to be promoted by such restrictions.51 The PSA contains 
instances of both pure and impure paternalism. The Act places restrictions on the 
autonomy of individual consumers and the psychoactive substances industry to protect 
the health and safety of individual consumers.  
 
 Gerald Dworkin proposed:52 
 
… it may be that impure paternalism requires arguments or reasons of a stronger kind in 
order to be justified, since there are persons who are losing a portion of their liberty and 
they do not even have the solace of having it be done “in their own interest”. 
 
He advocated that this may be the case especially where the victim can avoid the harm as 
the “incurring of the harm requires, so to speak, the active cooperation of the victim”.53 
Under this analysis, individual consumers of psychoactive substances do actively decide 
to use them. Consequently, the paternalistic nature of the PSA, which restricts the 
freedom of the psychoactive substances industry, may be harder, albeit not impossible, to 
justify. Such state paternalism can, in reality, be justified by reference to the theories of 
individual autonomy and utilitarianism.  
B Individual Autonomy 
 
Immanuel Kant declared that an individual can only make autonomous decisions when 
his or her choices are consistent with the categorical imperatives.54 A categorical 
imperative is defined as a “requirement that binds anybody, regardless of their 
inclinations”.55 One example of a categorical imperative is Kant’s “formula of universal 
law, [that one should] ‘act only on that maxim through which you can at the same time 
will that it should become universal law’”.56 Individuals are only permitted to act 
  
51  At 260.   
52  At 260.  
53  At 260.    
54  Immanuel Kant Metaphysik der Sitten Paul Natorp (ed) (Reimer, Berlin, 1907) (translated ed:  
Mary Gregor (Translator) Immanuel Kant The Metaphysics of Morals (Cambridge University 
Press, Cambridge, 1991) at 51). 
55  Simon Blackburn “The Oxford Dictionary of Philosophy” (2013) Oxford Reference  
<http://www.oxfordreference.com>. 
56  Simon Blackburn, above n 55.  
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autonomously when the choices they make are morally capable of becoming universal 
laws:57 
 
… any action is right if it can coexist with everyone’s freedom in accordance with a 
universal law, or if on its own maxim the freedom of choice of each can coexist with the 
freedoms of everyone in accordance with a universal law. 
 
It would be an impractical universal law to allow everyone to consume high risk 
psychoactive substances that may cause significant harm to their individual health or to 
society in general. Kant also requires that for an individual’s autonomy to be respected, 
they must be acting in line with their own rational nature.58 Richard Dean, a 
contemporary philosopher, acknowledged that under Kant’s moral theory, a way to:59 
 
… sacrifice one’s own rational nature is to destroy oneself or one’s minimal rational 
nature altogether. This kind of sacrifice – [such as] taking permanently mind-altering 
drugs or the like – is probably what most naturally comes to mind when one thinks of 
sacrificing one’s rational nature. 
 
This proposition suggests that individuals who are prepared to accept the risk of 
permanent mental degradation by consuming harmful substances are acting in a manner 
that is inconsistent with their own rational nature. 
 
John Stuart Mill, a great supporter of liberalism and utilitarianism, also considered the 
extent of an individual’s right to autonomy. He asserted that:60  
 
…neither one person, nor any number of persons, is warranted in saying to another 
human creature of ripe years, that he shall not do with his life for his own benefit what he 
chooses to do with it. 
 
Mill argued that “with respect to his own feelings and circumstances, the most ordinary 
man or woman has means of knowledge immeasurably surpassing those that can be 
possessed by anyone else”.61 Nevertheless, Mill also limited the right of individual 
autonomy:62  
  
57   Immanuel Kant, above n 54, at 56. 
58  At 106.  
59  Richard Dean “The Formula of Humanity as an End in Itself” Thomas Hill (ed) The Blackwell  
Guide to Kant’s Ethics (Blackwell Publishing Ltd, Oxford, 2009) 83 at 92.  
60  John Stuart Mill On Liberty (2nd ed, John W Parker and Son, London, 1859) at 136. 
61  At 137. 
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 … to human beings in the maturity of their faculties. We are not speaking of children, or 
of young persons below the age which the law may fix as that of manhood or 
womanhood. Those who are still in a state to require being taken care of by others, must 
be protected against their own actions as well as external injury. 
 
Contemporary philosophers, Tom Beauchamp and James Childress have defined 
autonomy as “self-rule that is free from both controlling interference by others and from 
limitations, such as inadequate understanding that prevent meaningful choice”.63 This 
proposition, that an individual needs to possess an adequate understanding of their 
choices before they can make an autonomous decision, holds merit. It is apparent that 
some individual consumers would not have used psychoactive substances if they fully 
comprehended the harms that such substances may inflict.64  
 
Rebecca Walker also considered the notion of “rational autonomy”.65 Under this 
conception, if an individual is aware that a substance causes harm to individual health, 
and yet, he or she consumes that substance on the basis that they did not believe it would 
cause them harm, that individual would be acting irrationally. It may be that the 
individual possesses all the relevant information, and yet at the same time, does not 
adequately understand that information. 
 
The PSA, considered in Part VIII of this paper, is inherently paternalistic and imposes 
significant restrictions on individual autonomy. The purpose of the PSA refers only to 
protecting the health and safety of individuals rather than for the benefit of society in 
general.66 Whilst the PSA is able to be justified under the Kantian theory, it can generally 
be perceived as in conflict with Mill’s theory of individual autonomy and liberty unless 
further consideration is given.  
1 Does the existence of substance dependence interfere with an individual’s autonomy? 
 
                                                                                                                                                 
62  At 22-23. 
63  Tom Beauchamp and James Childress Principles of Bioethics (6th ed, Oxford University Press,  
New York, 2009) at 99. 
64  Rebecca Ryan, “Teen’s horrific tangle with legal highs” The New Zealand Herald (online ed,  
Oamaru, 19 July 2013) <http://www.nzherald.co.nz>. 
65   Rebecca Walker “Respect for Rational Autonomy” (2009) 19(4) Kennedy Institute of Ethics  
Journal 339 at 340. 
66  Psychoactive Substances Act, s 3.  
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Robert Goodin considered “whether, in the case of smoking, the active cooperation of the 
smoker really is such as to constitute voluntary acceptance of the consequent risks of 
illness and death”.67 He asserted that “obviously, people cannot voluntarily accept the 
health risks of smoking if they do not know what they are”.68 Furthermore, even in the 
situation where an individual understood the potential risks to his or her health, informed 
consent could be inadequate because of substance dependence.69 For example, in the 
United States, up to 95 per cent of adults addicted to cigarettes “are thought to have been 
addicted before coming of age”.70 This is referred to as the “crux of the matter” 
whereby:71  
 
…being below the age of consent when they first began smoking, smokers were 
incapable of meaningfully consenting to the risks in the first instance. Being addicted by 
the time they reached the age of consent, they were incapable of consenting later, either. 
 
Goodin permits state paternalism and limits individual autonomy on the grounds that 
smoking may have a disproportionate effect on vulnerable individuals and result in 
substance dependence.  
 
Substance dependence has been defined as “a compelling urge for and psychological 
dependence on an addictive substance to the degree that acquiring and using the 
substance becomes a priority in the person’s life”.72 The New Zealand Addiction 
Research Centre has claimed that “all mood-altering substances have the potential to 
form addictions”.73 Many psychoactive substances currently, and will in the future, come 
under this scope. Experts in various fields have advocated that the addiction an individual 
suffers to a substance may remove that individual’s ability to exercise their autonomy.74  
 
  
67  Robert E Goodin No Smoking: The Ethical Issues (University of Chicago Press, Chicago, 1989) at  
16. 
68  At 20.  
69  At 25. 
70  At 30. 
71  At 30. 
72  Andrew M Colman Oxford Dictionary of Psychology (Oxford University Press, New York, 2001)  
at 958. 
73  Centre for Addiction Research “Submission to the Health Committee on the Psychoactive  
Substances Bill 2013” at [2].  
74  Frank Koopmans and Srdjan Sremac “Addiction and Autonomy: are Addicts Autonomous”  
(2011) 9 Nova Prisutnost 171 at 179.   
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According to Harry Frankfurt:75  
 
… addicts are not free because they have a first order desire to take heroin but a second 
order desire not to desire to take heroin… freedom of the will occurs when our first order 
desires are in line with our second order desires: we do what we desire to desire to do.  
 
It therefore follows that if an individual has:76  
 
…lost the power of self-control, it would seem that he/she cannot be held responsible in 
the absence of that power. And that would mean that such a person should be protected 
from such a state, i.e. by restrictions on certain drugs.  
 
In recent years, there have been reports of situations where individuals under the 
influence of psychoactive substances have engaged in socially unacceptable activities to 
fund their habit. In 2011, a 15-year-old young man from Oamaru became a victim of 
substance dependence to unregulated psychoactive substances.77 Eventually, with 
assistance from his mother, the young man spent nine weeks in a psychiatric hospital to 
recover from his addiction to psychoactive substances. This case study establishes that 
the use of certain psychoactive substances may also result in substance dependence. 
Because of the aforementioned similarities which exist between psychoactive substances 
and cigarettes, it is logical that Goodin’s argument would also apply to the use of 
psychoactive products.  
 
This paper proposes that the restriction on individual autonomy that arises as a result of 
the PSA is justifiable. It is logical to control substances that may, when consumed by an 
individual, result in harm or substance dependence. Harms are caused by, and inflicted 
upon, individual consumers who are desperate to fund their habit.78 Prohibitions and 
controls over certain substances will have the potential to minimise the risk of addiction 
to psychoactive substances by determining which substances pose a medium or high risk 
of future addiction.79  
  
75  Frank Koopmans and Srdjan Sremac, above 74, at 179. 
76  At 182.   
77  Rebecca Ryan, above n 64. 
78  Rebecca Ryan, above n 64.   
79  Psychoactive Substances Act, s 11(3)(d). 
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C Utilitarianism and the Wider Interests of Society  
1 The utilitarian perspective 
 
Jeremy Bentham advocated the theory of utilitarianism. He focussed on the overall utility 
of an act or law and acknowledged that:80  
 
… every law is an evil, for every law is an infraction of liberty. Government… has but 
the choice of evils. In making that choice, what ought to be the object of the legislator? 
He ought to be certain of two things: 1st, that in every case the acts which he undertakes 
to prevent are really evils; and, 2nd, that these evils are greater than those which he 
employs to prevent them. 
 
A law is only justified if it addresses the issue of a greater evil within society. If a law 
causes more harm to society than it does well, then it cannot be perceived as promoting 
the best interests of society in general. 
 
John Stuart Mill also established the harm principle, whereby “the only purpose for 
which power can be rightfully exercised over any member of a civilised community, 
against his will, is to prevent harm to others”.81 For the legal regulation of psychoactive 
substances to be legitimate, it is not enough that it causes harm to the health of the 
individual consumer, it must instead cause harm to other members within society. 
2 The Māori perspective  
 
New Zealand society is diverse and consists of different cultural groups including Māori 
and Pākehā. As acknowledged by Grant Berghan:82 
 
… one of the key differences between Māori and non-Māori (pākeha/western) society is 
the Māori emphasis on the well-being of the group, as opposed to the western focus on 
the individual. 
 
  
80  Étienne Dumont (ed) Jeremy Bentham Traités de législation, civile et pénale (1st ed, Bossange,  
Père et Fils, Paris, 1820) (translated ed: R Hildreth (translator) Jeremy Bentham Theory of 
Legislation (2nd ed, Trübner, London, 1871) at 66). 
81  John Stuart Mill, above n 60, at 22. 
82  Grant Berghan “Māori point of view” Health Promotion Forum of New Zealand (March 2007)  
<http://www.hauora.co.nz>. 
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Māori have a traditionally strong collective identity, whereby decisions are often made by 
the whānāu, hapū and iwi: 83   
 
…whānau members will feel strongly that they share in the achievements of their kin, and the 
whānau may even make decisions for a member, usually in consultation with the person 
concerned.  
 
The Ministry of Health has acknowledged that under the: 84 
 
… traditional Māori approach, the inclusion of the wairua [the spiritual health], the role 
of the whānāu (family) and the balance of the hinengaro (mind) are as important as the 
physical manifestations of illnesses.  
 
If a Māori individual uses substances which cause an imbalance in their wairua it may 
also have an impact on the overall health of their whānāu, hapū and iwi collectively. 
Therefore, it is also necessary to consider the potential harm caused not only to individual 
consumers, but also to their whānāus, hapūs and iwis.  
3 The fiscal costs of psychoactive substance use within New Zealand 
 
The clinical director of the Waikato Hospital Emergency Department, Dr John Bonning, 
reported that there was: 85 
 
… a considerable increase in recent visits to hospital emergency departments nationwide, 
[prior to the enactment of the PSA], by people experimenting with synthetic drug K2 
[that was] holding up the treatment of worthy emergency cases.  
 
This demonstrates that hospitals were, prior to the PSA, becoming inundated with 
individual consumers of psychoactive substances who had suffered adverse reactions. 
 
Furthermore, the Business and Economic Research Ltd (BERL) report produced for the 
Ministry of Health also reported that drug-related costs, excluding alcohol, under the 
  
83  Mauri Ora Associates “Best health outcomes for Māori: Practice implications” (December 2008)  
Medical Council of New Zealand <http://www.mcnz.org.nz>. 
84  Mason Durie “Te Whare Tapa Whā” (1985) Ministry of Health <http://www.health.govt.nz>. 
85  Danielle Nicholson “K2 Victims Clog Hospital EDs” Hamilton News (Hamilton, 21 June 2013) at  
1.  
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criminal sector in 2005/2006 amounted to $394,900,000.86 These statistics determine that 
scheduling and controlling harmful drugs in New Zealand requires significant financial 
expenditure from society. As this paper has already established, psychoactive substances 
have the potential to cause harm similar to that caused by substances prohibited under the 
MoDA. Consequently, it is apparent that these psychoactive substances may also impose 
large financial costs on the government and society.  
 
The BERL report also established that $129,700,000 of the total drug-related cost in 
2005/2006 was used to imprison individuals for drug-related offences.87 This indicates 
that if all psychoactive substances were controlled under the MoDA as illicit substances, 
the cost to the taxpayer of maintaining the justice sector would increase. Considering it is 
estimated that certain psychoactive substances pose only a low risk of harm to individual 
consumers and society, making individual possession of a psychoactive substance an 
offence which carried a prison term would be excessive. It is important that the legal 
ramifications for individual possession of psychoactive substances are reasonable and, at 
the same time, are able to act as a deterrent. The PSA, analysed further in Part VIII of this 
paper, successfully provides a good balance whereby individual possession is met by 
reasonable monetary fines rather than imprisonment. 
4 The non-fiscal harms resulting from the use of psychoactive substances  
 
The New Zealand Nurses Association has submitted “that nurses observe and are also 
harmed from aggressive and psychotic behaviours induced by party pills similar to those 
caused by banned Class A and Class B drugs”.88 This shows that medical professionals, 
who are treating individuals suffering from adverse reactions to psychoactive substances, 
are also at risk of being harmed. The New Zealand Police Association (NZPA) also 
submitted that there was: 89 
 
… a clear link between an increase in addiction to legal highs and an increase in crime - 
aggravated robbery and theft of legal highs from dairies and other retail outlets as people 
steal to fuel their addiction. 
  
86  Business and Economic Research Ltd “Costs of Harmful Alcohol and Other Drug Use” (March  
2009) at 69. 
87  At 65. 
88  New Zealand Nurses Association “Submission to the Health Committee on the Psychoactive  
Substances Bill 2013” at [5]. 
89  New Zealand Police Association “Submission to the Health Committee on the Psychoactive  
Substances Bill 2013” at [3]. 
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This is consistent with the assertion from the 15-year-old young man from Oamaru, 
mentioned above, who reported that, at the crux of his addiction to psychoactive 
substances, he spent around $200 a day on those substances and broke into over 300 cars 
to steal the possessions inside to fund his habit.90 The NZPA also reported an “increase in 
violent episodes and domestic violence attributed to legal highs”.91 
 
It is evident that the use of psychoactive substances by individuals may also cause harm 
to society in general. The PSA creates a regulatory scheme that aims to prevent the 
dangerous consumption of psychoactive products by individuals. Such regulation will 
reduce the level of criminal activity executed by individuals under the influence of such 
substances. Furthermore, the Act will also minimise the costs attributed to providing 
healthcare to individuals who suffer adverse reactions to harmful psychoactive 
substances.  
 
VII Was the Misuse of Drugs Act Sufficient to Control the use of 
Psychoactive Substances in New Zealand? 
 
The MoDA establishes whether a substance is illegal under New Zealand law and, if so, 
what the penalties are for manufacturing, selling, or using the controlled substance. In 
2011, the Law Commission released a report on the MoDA. This report confirmed that 
the lack of a regulatory regime for psychoactive substances that came outside the scope 
of the MoDA was problematic. It identified that:92 
 
…new psychoactive substances can be manufactured, imported and sold without 
restriction until they are proven to be harmful and scheduled either as restricted 
substances or controlled drugs…there is in practice a significant time lapse between when 
new substances start to become available for use and when authorities have gathered 
sufficient evidence on patterns of use and their effects to determine whether they should 
be scheduled and regulated or prohibited.  
A Temporary Class Drug Notice Mechanism 
 
  
90  Rebecca Ryan, above n 64.  
91  New Zealand Police Association, above n 89, at [3]. 
92  Law Commission Controlling and Regulating Drugs: A Review of the Misuse of Drugs Act 1975  
(NZLC R122, 2011) at 25-26.  
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In August 2011, Parliament amended the MoDA to allow the Minister of Health (the 
Minister) to issue Temporary Class Drug Notices (TCDN).93 This mechanism allowed the 
Minister to “prohibit for a 12-month period,94 the importation, manufacture, sale and 
supply of substances listed by a notice in the Gazette”.95 Substances that were subject to 
TCDNs were to be treated the same as Class C drugs under the MoDA.96   
1 The onus to prove a substance poses, or may pose, a risk of harm 
 
Under the TCDN mechanism, the onus was on the Minister to prove that a substance 
posed, or may have posed, a risk of harm. Section 4(3) stated that:97 
 
… the Minister must not give notice under subsection (1) unless he or she is satisfied that 
the substance, preparation, mixture, or article that is to be specified in the notice poses, or 
may pose, a risk of harm to individuals, or to society. 
 
This provision allowed harmful psychoactive substances to be sold to the public until the 
Minister was able to gather enough evidence to satisfy this requirement.  
2 Time constraints  
 
TCDNs could only come into effect seven days after they had been published in the 
gazette.98 This provision existed to provide manufacturers, importers, and retailers notice 
that they were required to remove products that contained the listed substances from their 
premises. However, in reality, it also provided manufacturers, importers and retailers an 
extra week in which they could offload harmful products onto the public.  
 
The 12-month duration of a TCDN was also unsatisfactory.99 The process of gathering all 
the necessary information required to determine whether or not a product would pose a 
risk of harm was often time consuming. For example, the substance GHB was available 
for two years before the government was able to classify it as a controlled substance.100   
  
93  Misuse of Drugs Act, s 4C.  
94  Section 4E(1)(a). 
95  Ministry of Health Regulatory Impact Statement, above n 24, at 19; Misuse of Drugs Act, s 4C(1). 
96  Misuse of Drugs Act, s 4D.  
97  Section 4C(3).  
98  Section 4C(6). 
99  Section 4E(2). 
100  Ministry of Health Regulatory Impact Statement, above n 24, at 23. 
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3 Analogous substances  
 
The TCDN mechanism stated “a substance that has a structure substantially similar to a 
temporary class drug [was] not to be treated as a controlled drug analogue by reason only 
of that similarity”.101 This created a situation in which manufacturers were able to make 
minor alterations to the chemical composition of a substance so that it could be sold 
again.102 However, the Law Commission previously recognised that “it is unsatisfactory 
to have the choice of regulatory approach for substances determined by such artefactual 
distinctions in chemical structure”.103 This is because:104  
 
… the focus on chemical structure does not take into account the extent to which 
analogue substances have the same or a similar impact … as their parent drug … 
Analogues will not necessarily behave in the same way or have a similar harm profile to 
their parent drug.  
 
The new mechanism under the PSA instead considers each individual psychoactive 
product to determine the level of risk a product may pose in accordance with the effects it 
has on individual health. This will ensure individuals are not prevented from consuming 
psychoactive products, which pose no more than a low risk of harm, merely because they 
share structural similarities with products which do pose a higher risk of harm.   
 
The aforementioned requirements under the MoDA were problematic. As established 
under Part VI, it is in the public’s interest for the state to act paternalistically and control 
the supply and use of harmful psychoactive substances. Without the existence of further 
regulation, it was difficult for the state to protect vulnerable individuals from the harmful 
effects of certain psychoactive substances. The reality was that the MoDA was entirely 
insufficient to deal with the global problem of psychoactive substances and a new 
regulatory system was required.  
 
VIII Is the Psychoactive Substances Act Sufficient to Control and Monitor 
Psychoactive Substances in New Zealand? 
 
  
101  Misuse of Drugs Act, s 4D(5).  
102  (9 April 2013) 689 NZPD 9133. 
103  Law Commission, above n 92, at 115. 
104  At 115-116. 
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The purpose of the PSA is to “regulate the availability of psychoactive substances in New 
Zealand to protect the health of, and minimise harm to, individuals who use psychoactive 
substances”.105 The PSA has reversed the onus that was previously on the Minister to 
prove a psychoactive substance posed a risk of harm.106 Instead, the onus is now on the 
manufacturers and importers of psychoactive products to prove to the Psychoactive 
Substances Regulatory Authority (the Authority)107 that each product they submit for 
approval only poses a low risk of harm to consumers.108  
 
The PSA is inherently paternalistic and restricts individual autonomy to protect people 
from making poor decisions based off a lack of understanding about the harms that some 
psychoactive products may cause. In this way, the PSA is restricting the autonomy of the 
very people it aims to protect. At the same time, the PSA inhibits the freedom of 
manufacturers, importers and retailers of psychoactive products. It is difficult to ascertain 
how the psychoactive substances industry will benefit from this new regulatory regime. 
Consequently, it is important to determine whether such restrictions are justifiable in 
accordance with Part VI of this paper.  
A What is the Scope of the Psychoactive Substances Act? 
 
This Act applies to the importation, manufacture, sale, supply, or possession of a 
psychoactive substance for the primary purpose of inducing a psychoactive effect in an 
individual who uses the substance.109   
 
For a substance to come under the ambit of the PSA it must have a “primary purpose of 
inducing a psychoactive effect”.110 This provision is in line with the NZDF’s recognition 
that “as most inhalants in New Zealand are common household products, it is not 
practical to make them illegal”.111 The NZDF also identified “although it is not illegal to 
possess inhalants, police can hold people under the influence of inhalants for 
detoxification under the Alcoholism and Drug Addiction Act 1966”.112 Whilst the use of 
  
105  Psychoactive Substances Act, s 3.  
106  Misuse of Drugs Act, s 4C(3). 
107  Psychoactive Substances Act, s 10.   
108  Section 37.  
109  Section 5(1). 
110  Section 5(1). 
111  New Zealand Drug Foundation “Inhalants and Solvents” (28 August 2013) <http://www.drug  
foundation.org.nz>. 
112  New Zealand Drug Foundation, above n 111.  
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such products by individuals for the purpose of obtaining a psychoactive effect is of 
concern, it would be impractical to require household items, such as petroleum, to pose 
no more than a low risk of harm before they can be provided to the public. In accordance 
with Dworkin’s analysis of state paternalism, it would be overly paternalistic of the state 
to prevent the proper use of such items by individuals who are not causing a risk of harm 
to themselves or to others in society.   
 
Nevertheless, the broad definition of “psychoactive substance” will still enable authorities 
to bring substances that are masqueraded as other products under the scope of the PSA. 
Iain Lees-Galloway MP has affirmed:113 
 
… anybody out there who thinks they can be a bit cute and try to call something by another 
name, and everybody knows it can be used as a psychoactive substance and can be ingested 
by a human being as a drug for a psychoactive effect—this clause will capture it. It does not 
matter what they call it.  
 
The provision Mr Lees-Galloway was referring to is now s 99 of the PSA. Section 99 
allows the Governor-General to declare a substance to be a psychoactive substance for 
the purposes of the Act. Substances that are used only for one purpose, to induce a 
psychoactive effect, and are masqueraded as another product may still be brought under 
the ambit of the PSA.114 Consequently, in situations where these items are consumed in a 
dangerous manner, a loophole exists whereby the state can still act paternalistically, in 
such a way where individual autonomy is infringed upon the least. 
B Are There Any Cultural Concerns that Arise as a Result of the Psychoactive 
Substances Act? 
 
Historically, psychoactive substances have been used by (i) priests in religious ceremonies 
(e.g. amanita muscaria); (ii) healers for medicinal purposes (e.g. opium); or (iii) the general 
population in a socially approved way (e.g. alcohol, nicotine and caffeine).115  
 
Psychoactive substances have been used by indigenous populations for centuries; and are, 
without a doubt, important to many cultures in New Zealand. However, it is uncertain as 
  
113  (9 July 2013) 692 NZPD 11777. 
114  Psychoactive Substances Act, s 99(1). 
115  Marc-Antoine Crocq “Historical and Cultural Aspects of Man’s Relationship with Addictive  
Drugs” (2007) 9(4) Dialogues in Clinical Neuroscience 355 at 355. 
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to whether substances, which pose more than a low risk of harm to individuals or society, 
should be permitted only because they are part of a cultural identity. 
1 Kava 
 
Kava is a prominent and pervasive force in daily life of the people in Fiji, Vanuatu, 
Tonga, the Samoas, and… other small island countries. This force or power has been 
interpreted in a number of ways, including as a link to the gods, maintaining a hierarchy 
in Pacific societies, as a mind altering drug, or as a symbol of national identity.116 
 
During the first reading of the PSA, Kris Faafoi MP identified how important kava was to 
certain communities within New Zealand:117 
 
… there is a lot of cultural significance attached to the ‘ava and kava ceremonies. For the 
Tongan community, for the Samoan community, and for the Fijian community it will be a 
psychoactive substance… 
 
The claimed health benefits of kava are also extensive:118  
 
…historically, kava was considered to have beneficial effects on health. The Hawaiians 
used it for many purposes, including to soothe the nerves, induce relaxation and sleep, 
counteract fatigue, relieve congestion in the urinary tract, alleviate symptoms of asthma 
and rheumatism, and reduce weight. 
 
Nevertheless, such claims are controversial. Recent studies have demonstrated that the 
consumption of kava produced by non-traditional means may also harm individual health. 
In 2008, the University of Sydney performed a study that found “following kavain 
treatmen … liver tissue displayed an overall change in structure”.119 Consequently, such 
“concerns about the dangers of kava and the effects on the liver have resulted in 
regulatory agencies … banning or restricting the sale of kava”.120 
 
  
116  Yadhu N Singh “Kava: An old drug in a new world” (2009) 71 Cultural Critique 107 at 109.   
117  (9 April 2013) 689 NZPD 9145. 
118  Yadhu N Singh , above n 116, at 119. 
119  Science News “Kava Linked to Liver Damage, New Evidence Shows” Science News (online ed,  
Maryland, 28 February 2008) <http://www.sciencedaily.com>. 
120  Science News, above n 119.  
27 The Law of Psychoactive Substances In New Zealand: The End of the Regulatory Game of Cat and Mouse  
 
As identified by Mr Faafoi, kava is not expressly excluded from the ambit of the Act.121 
Section 9, which defines the meaning of “psychoactive substance”, does not limit the 
scope of the PSA to substances which are only synthetic, otherwise known as chemical, 
in nature. Mr Dunne responded to this concern and asserted that “kava is already suitably 
regulated through other legislation and [the PSA] will have absolutely no effect on 
that”.122 The Australia New Zealand Food Standards Code, referred to under the Food 
Act 1981,123 regulates the traditional use of kava when it is consumed as a drink.124 
Consequently, the PSA excludes substances that are already regulated as “food” under the 
Food Act.125  
 
Mr Dunne declared that kava will also be covered by the Natural Health and 
Supplementary Products Bill 2013 (NHSPB).126 However, this assurance is entirely 
dependent on two uncertainties. Firstly, the NHSPB will have to be enacted for this to 
apply. Secondly, if the NHSPB is enacted, the PSA will have to be amended to stipulate 
that substances, which already come under the scope of the NHSPB, are excluded from 
the ambit of the PSA. Nevertheless, cl 9 of the NHSPB refers to a product that “is, or 
appears to be, manufactured for human use; and for the primary purpose of bringing 
about a health benefit to the person who uses the product”.127 If kava is consumed by an 
individual for the purpose of bringing about a health benefit, it may come under the scope 
of the NHSPB.  
 
The PSA provides a good balance, whereby traditional uses are permitted and other uses, 
which may cause individual harm, are restricted. The autonomy of different cultural 
groups within New Zealand will not be unduly infringed upon, and yet, harmful forms of 
kava, produced in a non-traditional manner, may still be prohibited in order to protect 
individuals who lack a sufficient understanding of the risks. Accordingly, this 
differentiation may help traditional users to distinguish between harmful and non-harmful 
forms of kava.   
  
121  (9 April 2013) 689 NZPD 9145. 
122  Peter Dunne “Dunne: Kava unaffected by Psychoactive Substances Bill” (press release, 11 April  
2013). 
123  Food Act 1981, s 2.  
124  Australia New Zealand Food Standards Code 2000, Standard 2.6.3.  
125  Food Act 1981, s 9(3)(f). 
126  Peter Dunne, above 122. 
127  Natural Health and Supplementary Products Bill 2013 (324-2), cl 6. 
28 The Law of Psychoactive Substances In New Zealand: The End of the Regulatory Game of Cat and Mouse  
 
2 Betel  
 
“Betel is a compound of several natural substances chewed for its mild psychostimulating 
effects.”128 It is believed that “approximately 200 million people chew betel regularly 
throughout the western Pacific basin and South Asia”.129 When betel is chewed it 
produces a psychoactive effect for the individual user and is often of cultural 
importance:130  
 
Betel and betel chewing are integral components of the cultural fabric for 20 [per cent] of 
the human population. The quantity, frequency, and age that one starts chewing betel 
vary by local traditions… in addition to its role in daily life, betel is a symbolic offering 
on occasions of welcoming guests and paying homage, courtship and betrothal, funerals 
and ancestral remembrances, reconciliation and peace-making, and in the practice of 
traditional medicine. 
 
The substances used to create betel are currently available in New Zealand.131 If it is 
brought under the ambit of the PSA, it is uncertain whether it will obtain approval as 
research has demonstrated that the regular use of betel may cause oral cancer to 
develop.132  
3 Should psychoactive substances that are linked to a cultural identity be excluded from 
the ambit of the Psychoactive Substances Act? 
 
This paper recognises that, on one hand, it appears logical in the interests of cultural 
understanding for substances that are created and used in a traditional manner to be 
excluded from the ambit of the Act. Section 99 would allow the Governor-General to 
declare traditional substances, such as kava or betel, not to be psychoactive substances for 
the purpose of the Act. Previous prohibitions on traditional psychoactive substances have 
also been linked to a lack of cultural collectiveness in certain communities and an 
  
128  Scott A Norton “Betel: Consumption and Consequences” (1998) 38(1) Journal of American  
Academy of Dermatology 81 at 81.  
129  At 81.  
130  At 83.  
131  P Yoganathan “Betel Chewing Creeps into the New World” (2002) 98 The New Zealand Dental  
Journal 40 at 40.  
132  Colin Binns, Wan Yun Low and Katie Hewitt “Betel Chewing and Public Health” (2011) 23(6)  
Asia-Pacific Journal of Public Health 1021 at 1021. 
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increase in violence.133 However, it would be illogical and undesirable, having 
determined that psychoactive substances pose a risk of harm that justifies state 
intervention, to allow certain substances to cause harm on the basis that they form part of 
a cultural identity. The risks to individual health may also justify the prohibition of such 
substances in order to protect society from related fiscal costs. Nevertheless, it seems 
unreasonable to place the burden of proving that a traditional psychoactive substance 
poses no more than a low risk of harm on the cultural community of which PSA 
adversely affects. Instead, this paper proposes that the burden to pay for the testing of 
such substances should be placed on the state.   
C Is the Requirement that all Individuals and Body Corporates must have Licences to 
Import, Manufacture, Research or Sell Psychoactive Substances Warranted? 
 
1 Interim Licences  
 
The PSA allows for a “transitional arrangement”, whereby a “psychoactive substance or 
product may continue to be imported, manufactured, researched, or sold after the 
commencement of [the Act]”,134 provided that it has “lawfully being imported, 
manufactured, researched, or sold throughout the period of 3 months immediately before 
the commencement of [the] Act.135 If importers, manufacturers, researchers and retailers 
want to continue importing, manufacturing, researching or selling such products during 
this transitional period, they must apply for, and obtain, an interim licence. 136 
 
Each applicant for a licence must provide “written consent… for the Authority to access 
any personal information about the applicant relevant to the application, including 
(without limitation) any police records”.137 The Authority may then use the information 
provided to determine whether an applicant is a fit and proper person to hold such a 
licence. Since the enactment of the PSA, two licences have been refused, two licences 
have been suspended, and one licence has been cancelled by the Authority.138 
  
133  Sione Pinomi “Kava restriction puts an unfair burden on Pacific culture” The Sydney Morning  
Herald (online ed, Sydney, 30 May 2013) <http://www.smh.com.au>. 
134  Psychoactive Substances Act, sch 1(2).  
135  Schedule 1(2). 
136  Schedule 1(2).  
137  Schedule 1(7)(3).  
138  Ministry of Health “Interim Licences” (03 October 2013) <http://www.health.govt.nz>.  
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Psychoactive substances are able to cause significant harm to individual consumers and 
society. Therefore, it is important to ensure that individuals, who have previously 
demonstrated a lack of regard for the wellbeing of individuals and society, are excluded 
from dealing in psychoactive products. Since the enactment of the PSA, approximately 
110 retail licences have been issued.139 However, once the Psychoactive Substances 
Regulations come into effect, interim licences will be revoked unless, within 28 days 
after the establishment of the regulations, the individual or body corporate completes a 
full application for a licence under s 13 of the PSA.140 
2 Applications for licences  
 
Licences under the PSA must be obtained before an individual or body corporate can 
import psychoactive substances,141 manufacture psychoactive substances,142 research 
psychoactive substances,143 sell psychoactive substances that are not approved 
products,144 sell approved products by retail,145 and sell psychoactive substances by 
wholesale.146 In order to obtain any of these licences, the application made must include 
“any particulars, information, documents or other material required by the Authority and 
prescribed in the regulations”147 and “the prescribed fee”.148  
 
This mandatory requirement is an instance of impure paternalism, whereby the state 
prohibits unlicensed individuals and body corporates from manufacturing, importing and 
selling psychoactive substances to protect the health of individual consumers. Such state 
intervention is justified because of the extensive amount of harm that unregulated 
psychoactive substances may impose on individual consumers and society. Prior to the 
enactment of the PSA, the psychoactive substances industry took advantage of the lack of 
regulation to sell high risk psychoactive products for financial gain.149 To allow such 
  
139  Todd McClay “Psychoactive Substance retailers banned from trading” (press release, 29  
September 2013). 
140  Psychoactive Substances Act, sch 1(9). 
141  Section 13(1)(a). 
142  Section 13(1)(b). 
143  Section 13(1)(c). 
144  Section 13(1)(d). 
145  Section 13(1)(e). 
146  Section 13(1)(f). 
147  Section 13(2)(b)(i). 
148  Section 13(2)(b)(ii). 
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31 The Law of Psychoactive Substances In New Zealand: The End of the Regulatory Game of Cat and Mouse  
 
individuals and corporations to remain unlicensed and unregulated would impose an 
unacceptable risk of harm on individuals and society.  
 
Section 16(1)(c) requires that “for an application made by an individual, the applicant is a 
fit and proper person to hold the licence”. Section 16(2) outlines what the Authority shall 
consider when determining whether a person is “fit and proper” to hold a licence: 
 
(a)  whether the applicant has been convicted of a relevant offence; and 
(b)  whether there has in the past been a serious or repeated failure by the applicant to 
comply with any requirement of this Act; and 
(c)  whether there are other grounds for considering that the applicant is likely in the 
future to fail to comply with any requirement of this Act; and 
(d)  any other matter that the Authority considers relevant. 
 
The term “relevant offence” is defined in section 16(3) as including:150 
 
(a)  an offence against this Act; or 
(b)  an offence against the Misuse of Drugs Act 1975 or the Misuse of Drugs 
Amendment Act 2005 or any regulations made under those Acts; or 
(c)  an offence against the Medicines Act 1981; or 
(d) a crime involving dishonesty (as defined in section 2(1) of the Crimes Act 1961). 
 
It would be illogical to allow applicants, who have previously disregarded laws designed 
to protect the safety of individual consumers, the opportunity to cause further harm to 
such individuals. Section 16(1)(d) also requires “for an application made on behalf of a 
body corporate, [that] the body corporate is of good repute”.151 No definition or method 
of determining whether a body corporate is of good repute is provided under the Act. 
Consequently, the Authority will have to interpret the term without further guidance each 
time they consider an application from a body corporate.  
 
Licences granted by the Authority will generally last for 3 years from the date of issue.152  
Section 22(1)(d) allows for the suspension or cancellation of licences where a licence 
holder has ceased to be a fit and proper person to hold a licence, or a body corporate of 
good repute. This provision will ensure that licences continue to be held only by 
  
150  Section 16(3). 
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individuals and body corporates who are willing to comply with the requirements under 
the PSA. 
3 Offences relating to licences 
 
Section 24 establishes that it is an offence to provide materially false or misleading 
information during the application process.153 Any person who commits this offence “is 
liable on conviction to a term of imprisonment not exceeding 3 months or a fine not 
exceeding $500,000, or both”.154 The substantial penalties imposed for this offence are 
justified. The licencing regime under the PSA has a purpose of excluding undesirable 
individuals from obtaining such licences. The penalties imposed under s 24 will dissuade 
individuals who are not “fit and proper” to hold such licences, from providing false 
information in an attempt to obtain a licence.  
 
Sections 25-26 also provide penalties for importing or manufacturing psychoactive 
substances without a licence.155 The penalties for importing or manufacturing 
psychoactive substances without a licence are:156  
 
(a)   in the case of an individual… a term of imprisonment not exceeding 2 years  
(b)  in the case of a body corporate…  a fine not exceeding $500,000 
 
Section 27 also establishes that any individual who sells an approved product without 
possessing a licence is liable to a “term of imprisonment not exceeding 3 months, or a 
fine not exceeding $40,000”.  
 
These penalties are valuable as they will dissuade individuals who are unwilling to 
comply with the requirements under the Act from manufacturing or importing 
psychoactive substances. By ensuring all importers, manufacturers, and retailers of 
psychoactive products are licenced, enforcement officers will know which individuals 
and body corporates are dealing in psychoactive substances and products. As a result, 
they will be able to monitor such individuals and body corporates to ensure continuous 
compliance with the PSA.  
  
153  Section 24(1). 
154  Section 24(2). 
155  Sections 25-28. 
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D How can a Psychoactive Product Become an Approved Product? 
 
Section 4(a) states “a psychoactive product that is approved for use by individuals should 
pose no more than a low risk of harm to individuals who use it”.157 The PSA ensures that 
each individual psychoactive product must be proven to pose no more than a low risk of 
harm before it can be sold to the public. Even if a psychoactive product includes the same 
ingredients as a previously approved product, it will still be required to gain approval 
through the Authority. Each individual product will be evaluated under the PSA, which 
means that harmful products will not be able to be masqueraded as something they are 
not.  
1 Interim approvals of psychoactive products  
 
The PSA establishes that “a person who is a New Zealand resident may, within 28 days 
after the commencement of this Act, apply for the interim approval of a psychoactive 
product”.158 The transitional arrangement under the PSA allows psychoactive products, 
which were lawfully sold within the three month period prior to the enactment of the 
PSA, to continue to be imported, manufactured, researched or sold.159 Although 
applicants are not required to provide information from preclinical and clinical trials, the 
applications for the interim approval of products are heavily scrutinised by the Authority 
and the Interim Psychoactive Substances Expert Advisory Committee (IPSEAC).160  
 
The Authority has established a temporary risk assessment method to determine whether 
a psychoactive product poses more than a low risk of harm. “Products with a combined 
risk score of greater than [two] pose more than a low risk of harm to a consumer.”161  The 
risk level of a product is determined by reference to the reported number of adverse 
effects. Each minor adverse effect is given a score of one, a moderate adverse effect is 
given a score of two, a severe adverse effect is given a score of three, and each adverse 
effect relating to withdrawal is given a score ranging from one to three.162 Consequently, 
an application for interim approval of a product will be rejected if, for example, three 
individuals have previously suffered minor adverse effects after consuming the 
  
157  Section 4(a). 
158  Schedule 1(3). 
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psychoactive product. Since the enactment of the PSA, the Authority has “refused 
applications for six products seeking interim approval”.163 These products were denied 
approval due to the various “reports of adverse reactions from a range of sources 
including the National Poisons Centre and hospital emergency departments”.164 The 
Authority has acknowledged that it is acting on the side of caution, whereby, products 
must pose only a very low risk of harm to obtain interim approval.165  
2 Applications for Approval of a Product  
 
The Authority has declared that once the Psychoactive Substances Regulations are in 
place, individuals applying for the approval of a product:166 
 
… will be required to submit a research plan designed to conclusively demonstrate the 
product poses no more than a low risk of harm to a consumer along with data on the 
safety and quality of their product. 
 
The degree of harm a psychoactive product poses to individual consumers will be 
determined by the Authority.167 To assist the Authority with this task, the Psychoactive 
Substances Expert Advisory Committee (PSEAC) will analyse the available information 
on each product and advise the Authority accordingly.168 As acknowledged by the current 
Associate Minister of Health, the Hon Todd McClay MP, the PSA “was never meant to 
be a ban by stealth”.169 Accordingly, the PSA states that “a psychoactive product that 
poses no more than a low risk of harm to individuals who use the product should be 
approved”.170 At the same time, the focus on individual health and safety is affirmed by s 
4(d) which states “a psychoactive product that poses more than a low risk of harm to 
individuals who use the product should be prohibited”.171 Section 4(e) also prohibits all 
psychoactive products on a precautionary basis until they have been approved by the 
Authority.  
 
  
163  Fuseworks Media “Authority refuses approval for psychoactive products” Voxy (online ed, New  
Zealand, 27 September 2013) <http://www.voxy.co.nz>.  
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Section 37 establishes the grounds for approving a product:172 
 
The Authority must approve a psychoactive product as an approved product if the 
Authority is satisfied that –  
(a) the application relating to the product –  
  (i) complies with the requirements of section 33; and  
  (ii) does not contain any materially false or misleading information; and  
(b) the degree of harm that the product poses to individuals using the product is no 
more than a low risk of harm 
 
For an application to be approved, the applicant must have complied with s 33. Section 
33(2) stipulates that an individual applying for approval of a product must provide any 
information that the Authority requests. This provision is a key component of the PSA, as 
such information will enable the Authority to make an informed and accurate assessment 
of the risk of harm a product may pose to consumers.  
 
Section 33(2) also requires the applicant to pay “the prescribed fee (if any)”.173 The 
Psychoactive Substances Regulations, expected to be in place by late 2013, will stipulate 
the “processes and fees required for new product approvals”.174 However, Mr Dunne 
acknowledged that each application for approval of a product will cost up to $180,000.175 
It has also been estimated that the testing of an individual product will cost around 
$2,000,000.176 These costs are reasonable when one considers that the individuals who 
will be applying for approval are representatives of corporate bodies. These corporations 
have made substantial profits over the years through the sale of psychoactive substances 
and will continue to do so after approval is granted.177 
3 Offence relating to application for approval 
 
Section 41(1) states:  
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A person commits an offence in respect of an application for the approval of a 
psychoactive product if the person –  
(a) provides information that the person knows, or ought to know, is 
materially false or misleading; or  
(b) fails, without reasonable excuse, to provide any relevant information 
relating to –  
(i) the ingredients of the product; or  
(ii) the effect of the product on individuals who use the product.  
 
Section 41(2) establishes that a person who commits an offence under s 41(1) “is liable 
on conviction to a term of imprisonment not exceeding 3 months or a fine not exceeding 
$500,000, or both”. The penalties for this offence are substantial, however, the 
information gathered on each psychoactive product submitted for approval enables the 
Authority to ensure only low risk products are made available to the public. It would be 
illogical to allow applicants to provide false information or to mislead the authority about 
the risk level of a product. If an applicant fails to inform the authority about a potential 
adverse effect that a product may cause, and that product is subsequently approved, it 
may have serious implications for an individual consumer who later suffers that adverse 
reaction. As a result, it is important to restrain the actions of the psychoactive substances 
industry, and impose substantial penalties for non-compliance with the Act, to protect 
consumers and society from such instances of harm.  
E How Will the Authority Determine Whether a Psychoactive Product Poses Only a 
Low Risk of Harm? 
 
The PSEAC will “evaluate, with regard to the results of trials, psychoactive products to 
assess whether they should be approved for use by individuals”,178 and “advise the 
Authority about whether a psychoactive product should or should not be approved for use 
by individuals”.179 Section 11(4) states that:180  
 
… the advisory committee may comprise up to 6 members who between them must 
have appropriate expertise in –  
(a) pharmacology: 
(b) toxicology:  
  
178  Psychoactive Substances Act, s 11(2)(a). 
179  Section 11(2)(b). 
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(c) neurosciences: 
(d) medicine: 
(e) any other areas the Authority considers relevant 
 
This provision establishes that members of the PSEAC will be required to combine 
knowledge in different areas of expertise to ensure only psychoactive products that pose a 
low risk of harm are approved. This provision provides a much greater level of guidance 
to the Authority than the current method of establishing Ministerial committees provides 
to the Minister of Health under the New Zealand Public Health and Disability Act 2000 
(NZPHDA). Section 11(1)(b) of the NZPHDA establishes that the Minister may  “appoint 
any person to be a member or chairperson of the committee”.181 No further guidance is 
provided in the NZPHDA as to which fields of expertise members should be familiar 
with. Furthermore, with the exception of the four members chosen by the Minister, the 
majority of each District Health Board (DHB) in New Zealand is comprised of members 
who have been voted in by the New Zealand public.182 Consequently, is uncertain 
whether the use of this method produces a DHB that possesses the necessary level of 
medical and legal knowledge. 
 
Section 11(4)(e) establishes that the Authority may choose members from other fields of 
expertise.183 This will, in theory, allow a legal professional to be appointed as a member 
of the PSEAC. Section 11(10) determines that the PSEAC must “act independently; and 
… comply with natural justice”.184 The inclusion of a legal professional may help to 
ensure that the processes comply with these legal requirements, and subsequently, may 
lead to fewer appeals.185 
 
The Centre for Addiction Research has also advocated that a specialist in the field of 
addiction should be a member of the PSEAC.186 An expert in addiction may be able to 
determine whether the use of a psychoactive product is likely to cause individual 
consumers to become dependent on that psychoactive product. This will help to minimise 
the harms caused by such dependence, including the injuries to individual health and 
fiscal costs to society.  
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To assist the PSEAC with establishing whether a product will pose only a low risk of 
harm, the Health Select Committee established a list of matters to which the PSEAC must 
have regard:187 
 
(a)  the specific effects of the product, including pharmacological, psychoactive, and 
toxicological effects; and 
(b)  the risks, if any, to public health; and 
(c) the potential for use of the product to cause death; and 
(d)  the ability of the product to create physical or psychological dependence; and 
(e)  the likelihood of misuse of the product; and 
(f)  the potential appeal of the product to vulnerable populations; and 
(g)  any other matters that the Authority considers relevant. 
1 “The specific effects of the product including pharmacological, psychoactive, and 
toxicological effects” 
 
This provision is essentially vague and does not explicitly preclude the PSEAC from 
considering both the positive and negative effects of a product. Consequently, this 
provision may allow the PSEAC to perform a balancing act, whereby the positive aspects 
of a product may be weighed against the negative aspects of a product.  
 
Furthermore, little information is provided as to whether the long-term effects of a 
product will be considered by the PSEAC. It is foreseeable that certain adverse effects, 
which arise from the use of psychoactive substances, will only occur after prolonged use 
of a product. For example, the regular use of betel over a prolonged period of time may 
cause oral cancer to develop years after the date of initial consumption.188 
2 “The risks, if any, to public health” 
 
This requirement makes it apparent that, despite not being mentioned as a purpose or 
principle under the PSA, the Act, in reality, regulates psychoactive substances in order to 
provide protection not only to individual consumers, but also to society in general. 
However, it is uncertain as to whether this requirement would protect society from many 
of the harms, identified in Part V of this paper, which may result from the use of 
psychoactive substances. For example, it is unlikely that the potential for the use of a 
product to impose significant financial costs upon society will be considered under this 
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39 The Law of Psychoactive Substances In New Zealand: The End of the Regulatory Game of Cat and Mouse  
 
provision. Instead, it is likely that the Authority will have to utilise its own discretion and 
incorporate such concerns under “any other matters that the Authority considers 
relevant”.189 
3 “The potential for use of the product to cause death” 
 
The study generated on the past use of GHB, considered in Part V of this paper, 
demonstrated that the use of certain psychoactive substances may result in death. If the 
use of a psychoactive product is able to cause the death of an individual consumer, it 
certainly poses more than a low risk of harm and should certainly not obtain approval 
under the PSA.  
4 “The ability of a product to create physical or psychological dependence” 
 
Section 11(3)(d) addresses the concern that some psychoactive substances may pose a 
long term risk of substance dependence. As previously established in Part VI, the 
existence of substance dependence may negatively affect an individual’s ability to 
exercise their right to autonomy. It would be illogical to allow addictive psychoactive 
products to be consumed by individuals, who may, like the young man in Oamaru, resort 
to criminal activities in an attempt to fund their habit.190 
5 “The likelihood of misuse of the product” 
 
The PSEAC’s consideration of this factor may be useful in situations where information 
is available which demonstrates that a psychoactive product has, prior to the PSA, been 
consumed regularly by individuals in quantities that are higher than the recommended 
dosage. However, when an application is for a product that contains only new 
psychoactive substances, which have never before been available to the public, the 
likelihood of misuse may be difficult to determine.  
6 “The potential appeal of the product to vulnerable populations” 
 
As identified by Mill, some individuals, including minors, lack the ability to make good 
autonomous decisions.191 The PSA imposes various restrictions on the psychoactive 
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substances industry in an attempt to ensure that minors are not exposed to, or attracted by, 
psychoactive products. This consideration will allow the PSEAC to determine whether 
features, such as the name or contents of a product, have the potential to appeal to minors 
or other vulnerable populations.   
F What Level of Evidence will be required by the Authority to determine whether a 
Psychoactive Product poses only a Low Risk of Harm? 
 
Section 8 defines trial as “a preclinical or clinical trial, and includes research, testing and 
teaching”.192 Section 4(b) stipulates that the Authority should have regard to evidence, 
which includes the results of preclinical and clinical trials, before a product is 
approved.193 Preclinical trials involve a laboratory test as part of the process of proving 
that there is a sufficient level of evidence to justify a clinical trial.194 They exist to 
determine “the starter range of doses to be tested in people, as well as the format to be 
used—syrup, capsule, pill or injection”.195 Medsafe has defined the term clinical trial as 
“the scientific study of a new device design, application, or treatment that is conducted to 
collect data on the safety and efficacy of the invention”.196 Whilst this is a good 
definition, the efficacy of psychoactive products will not be considered by the PSEAC.197  
The PSA does not specify how extensive trials will have to be; however, it is apparent 
that the information gathered must be of an adequate level for the PSEAC and the 
Authority to determine whether a product poses only a low risk of harm.  
 
The Centre for Addiction Research submitted that the required trials should be performed 
by a set body of independent researchers.198 The pharmaceutical industry has often been 
criticised for the manufacturer’s ability to publish and provide only information which 
supports their case.199 If manufacturers and importers are able to omit evidence, which 
establishes that certain products pose more than a low risk of harm, individual consumers 
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would often be unable to make an informed decision on whether to use such psychoactive 
products. 
 
Despite the list of effects and potential harms that the PSEAC must have regard to, there 
are still matters that require further consideration. A fundamental question, which 
remains to be answered, is whether the method of use will be tested for harmful effects. It 
has been established that smoke inhalation can have a detrimental effect on individual 
health and may cause throat cancer.200 In order for products to be entirely evaluated for 
the risks they pose to individual and public health, the method of consumption should 
also be evaluated during preclinical and clinical trials. 
 
An additional benefit to society is that the PSEAC will release reports on the substances 
that they have subjected to risk evaluations.201 The PSA also establishes an Internet-based 
register that will list the products that have gained approval.202 An important component 
of the PSA is the choice it provides to individual consumers. Consumers are able to 
choose to use psychoactive products that may pose a low risk of harm. In Part VI of this 
paper, Tom Beauchamp and James Childress considered that a proper understanding of 
the decision at hand is required before an individual can act autonomously.203 The reports 
released by the PSEAC will provide consumers with unbiased information about 
psychoactive products. As a result, individuals will have the opportunity to gain an 
understanding of the risks of each product and subsequently, will be able to make an 
informed decision on whether or not to consume a particular psychoactive product. 
G Where Can Psychoactive Products Be Sold or Supplied? 
 
The Law Commission recommended that:204  
 
 … the sale or supply of approved substances should be prohibited from:  
(a) places where alcohol is sold;  
(b) petrol stations;  
(c) non-fixed premises such as vehicles, tents and mobile street cars; and  
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(d) places where children gather (Such as schools, recreational facilities and sports 
facilities). 
 
Section 52 provides a list of places and premises at which psychoactive products are 
prohibited from being sold. Included in this list are dairies,205 convenience stores,206 
grocery stores and supermarkets,207 service stations,208 outlets that sell or provide 
alcohol,209 premises that are not a fixed permanent structure,210 any vehicle or other 
conveyance,211 and any other places or premises listed under potential future 
regulations.212 
1 Minimising the level of exposure to psychoactive products by minors 
 
These prohibitions on the sale and supply of psychoactive products were formed by the 
Health Select Committee in an attempt to minimise the level of exposure of such products 
to young persons. It is logical to assume that by removing these products from places 
where individuals under the age of 18 years old frequent, the level of exposure will 
decrease.  
 
Section 48(1) also stipulates that it is an offence for any individual to sell psychoactive 
products to other individuals under the age of 18 years old. Section 48(2) determines that: 
 
A person who contravenes subsection (1) commits an offence and is liable on conviction –  
(a)   In the case of an individual, to a fine not exceeding $5,000: 
(b)   In the case of a body corporate, to a fine not exceeding $10,000. 
 
These restrictions on where products may be sold, and to whom they may be sold to, are 
reasonable. The state already restricts the autonomy of minors for their own protection; 
for example, only individuals 18 years old and over can purchase alcohol in New 
Zealand.213 As acknowledged by Mill, young persons may often lack the level of maturity 
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or understanding required to make good autonomous decisions.214 If individuals cannot 
fully understand the risk of harm that psychoactive products may pose, their decision to 
use such products is uninformed. Consequently, the state is justified in limiting the 
autonomy of retailers to protect such vulnerable individuals from harm. 
 
2 The combined consumption of alcohol and psychoactive products  
 
The National Community Action Youth and Drugs Advisory Group submitted that 
“evidence from research on illicit drugs suggests the combined consumption of 
psychoactive substances and alcohol increases the misuse and immediate risk of harm 
from such drugs”.215 Such harm can also have an adverse effect on society as a whole, 
through both increased levels of violence,216 and the fiscal costs of hospitalisation for 
individuals who suffer adverse reactions.217 Section 52(1)(e) of the PSA, which prohibits 
the sale of psychoactive products at premises where alcohol is sold or supplied, will help 
to minimise this harm. Firstly, this provision will remove any implication that such 
substances may safely be consumed together because they can both be purchased from 
the same location.  Secondly, it will make it more difficult for individuals to obtain both 
substances at the same time. 
3 The quantity of psychoactive products that may be sold to an individual 
 
This paper proposes that it would be logical to limit the quantity of products a retailer 
may provide to an individual. Such a restriction would serve as a reminder to individual 
consumers that only the amount stipulated on the package of a product should be 
consumed.  
H How Can Psychoactive Products Be Advertised? 
 
The Law Commission recommended that the advertising of psychoactive products:218 
  
  
214  John Stuart Mill, above n 60, at 22-23.  
215  National Community Action Youth and Drugs “Submission to the Health Committee on the  
Psychoactive Substances Bill 2013” at [4].  
216  New Zealand Police Association, above n 89, at [3]. 
217  Danielle Nicholson, above n 85, at 1. 
218  Law Commission, above n 92, at 24-25. 
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… be prohibited except at the point of sale, either within premises where they are sold or 
supplied [and that] point of sale advertising should be confined to material that 
communicates objective product information, including the characteristics of the 
substance, the manner of its production and its price.  
 
Section 56 of the PSA severely limits the ability of a manufacturer, importer or retailer to 
advertise psychoactive products. Section 56(1) establishes that psychoactive products 
cannot be advertised via television, radio, any newspaper or publication, non-
psychoactive product-related Internet sites, or any subsequent mediums that may be 
prescribed through regulations at a later date.219 
 
Section 56(3) provides further restrictions in relation to where advertising may occur:220  
 
Advertising for an approved product (except a product sold by Internet sale)— 
(a) may appear only in premises where the approved product is sold; and 
(b)  must be confined to the inside of the premises; and 
(c)  must not be easily visible or audible from outside the premises; and 
(d)  must be limited to material that communicates objective information about the  
product, including (without limitation)— 
(i) the active ingredients of the product and the appropriate quantity of 
each active ingredient: 
(ii) the price of the product. 
 
Section 56(2) states that a person may not advertise a product in such a way that 
“particularly appeals” to minors. The restrictions on advertising established under the 
PSA will reduce the level of exposure to psychoactive products by minors. These 
restrictions are generally consistent with the Smoke-free Environments Act 1990, which 
determines that no person may publish a tobacco product advertisement, unless it is to 
display information such as the price of the product.221 In July 2012, the Smoke-free 
Environments Act was amended to prohibit retailers from placing tobacco products on 
display in their store, or from trading under a name that indicated they were selling such 
products.222 It has been reported that international research has indicated that “children 
  
219  Psychoactive Substances Act, s 56(1). 
220  Section 56(3). 
221  Smoke-free Environments Act 1990, s 22. 
222  Public Health Association “Tobacco display ban will improve New Zealanders’ health” (press  
release, 20 July 2012). 
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who regularly frequent stores with tobacco displays are twice as likely to take up 
smoking as those who visit such stores less often”.223  
 
Section 101(1)(b) states: 
 
The Governor-General may, by Order in Council made on the recommendation of the 
Minister, make regulations for 1 or more of the following purposes… 
(b) prescribing restrictions or prohibitions, or both, on the places or premises which 
approved products may be sold. 
 
It would be worthwhile for the Governor-General to create a regulation which restricts 
entry into premises dealing in psychoactive products to individuals 18 years old and over. 
This restriction would limit the exposure of psychoactive products to minors, and 
consequently, in line with the information available, would also reduce the number of 
individuals under the age of 18 years old from using such products.  
I What are the Labelling Restrictions and Requirements for Psychoactive Products? 
 
The PSA provides strict guidelines as to what may be present on the label of a 
psychoactive product. Section 58(1) states: 224 
 
… a label for an approved product must not be designed in a manner or way, or using a 
medium or form, so as to particularly appeal, or to be likely to particularly appeal, to 
minors.  
 
The label of a product must also provide the following information:225 
 
(a) a list of the active ingredients of the product and the appropriate quantity of each 
active ingredient; and  
(b) the appropriate health warning relating to the product; and 
(c) the contact details of the importer, manufacturer, wholesaler, or retailer of the 
product; and 
(d) the telephone number of the National Poisons Centre information service or any 
other telephone service prescribed in the regulations; and 
(e) any other information prescribed by the regulations. 
  
223  Public Health Association, above n 219.  
224  Psychoactive Substances Act, s 58(1).  
225  Section 58(2). 
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1 “The list of active ingredients” 
 
By requiring that the list of active ingredients are present on the label of a psychoactive 
product, the PSA affords consumers the ability to perform further research on those 
ingredients before they make their decision to use such products. Furthermore, if any 
adverse reactions do occur, medical professionals may be able to react faster to medical 
emergencies if the ingredients are readily available to them.   
2 “Appropriate health warning relating to the product” 
 
Section 60 requires that an appropriate health warning must be present on all labels of 
approved psychoactive products.226 Section 56(2)(a) also prohibits the use of advertising 
that promotes the product as being safe. These provisions work together to remove any 
false sense of security, held by consumers, which suggests that the use of psychoactive 
products is harmless.  
3 “Telephone number of the National Poisons Centre information service” 
 
The New Zealand National Poisons Centre has submitted that they receive a substantial 
amount of calls relating to incidents involving psychoactive substances, some from 
individuals as young as 11 years old.227 It is no doubt important that, if approved 
psychoactive products are to be continually monitored, such support services are 
contacted about adverse effects caused by approved products. Such notifications will not 
only enable medical practitioners to help individuals suffering from adverse side effects, 
but will also allow the Authority to be notified of such adverse reactions to approved 
products. Consequently, the Authority will be able to make such information available to 
the public and revoke the approval of a product if necessary.228  
J Should a Duty to Report Adverse Reactions Exist? 
 
“Adverse reaction” is defined under the PSA as:229  
 
  
226  Section 60.  
227  National Poisons Centre “Submission to the Health Committee on the Psychoactive Substances  
Bill 2013” at [5]. 
228  Psychoactive Substances Act, s 88. 
229  Section 8. 
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(a)  an unwanted or harmful reaction experienced by an individual who has used a 
psychoactive substance or an approved product; and  
(b)  that is suspected to have arisen from, or be related to the use of the substance or 
product 
 
The PSA imposes a duty on specified persons to notify the Authority about adverse 
reactions. Section 98 establishes “a person who holds a licence in respect of the 
psychoactive substance [and] …  the person who applied for approval of the approved 
product under s 33” must report any adverse reactions that arise from individual use of a 
psychoactive substance or a psychoactive product.230 This provision is important as it 
allows the Authority to re-evaluate the risk of harm a product may pose in light of the 
new evidence. Consequently, re-evaluated products found to pose more than a low risk of 
harm may be subjected to recall orders in order to remove the threat they pose to 
individual health and safety.  
 
The Health Select Committee considered whether medical practitioners should also have 
a responsibility under the Act to report adverse reactions caused by approved 
psychoactive products. On this question, the Health Select Committee decided that such 
mandatory reporting was unnecessary as the:231 
 
… voluntary reporting of reactions to medicines works well. Rather than including such a 
requirement in the bill, we recommend that the Ministry of Health work with medical 
practitioners on a voluntary system of reporting. 
 
The wording of the Act makes it apparent that less faith is placed on licence holders of 
psychoactive substances and persons applying for approval of psychoactive products.  If 
an offence is committed under s 98, an individual may be subjected to “a term of 
imprisonment not exceeding 3 months or a fine not exceeding $500,000, or both”.232 This 
penalty for non-compliance is substantial; however, both categories of persons listed 
under s 98 are financially dependent on the psychoactive substances industry. 
Consequently, such individuals would be less likely than a medical practitioner to 
voluntarily report adverse effects caused by their products. 
  
230  Section 98. 
231  Psychoactive Substances Bill (100-2) (commentary) at 7. 
232  Psychoactive Substances Act, s 98(4). 
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K Does the Ability for the Authority to Recall Approved Products provide a Sufficient 
Safeguard? 
 
Section 88 allows the Authority to issue recall orders to the importer, manufacturer, 
wholesaler, or retailer of an approved product.233 Section 88(4) limits this ability by 
providing a definition of recall order which requires that “the Authority has reasonable 
grounds to believe that the approved product poses more than a low risk of harm to 
individuals using the product”.234 
 
Section 88 allows the Authority to act on information that may arise after the preclinical 
and clinical trials of a psychoactive product have been completed. This provision is 
consistent with the purpose of the Act and allows the Authority to better protect minors, 
vulnerable individuals, and society in general from the harms that these products may 
cause. 
L Is the Appeal System Established under the Psychoactive Substances Act 
Adequate?  
 
Section 44 establishes the Psychoactive Substances Appeal Committee (PSAC).235 The 
PSAC must consist of three members, “each appointed by the Minister on any terms and 
conditions that the Minister thinks fit”.236 The only restriction on the composition of the 
PSAC is that one member must be a lawyer with at least seven years legal experience.237 
The PSA specifies that “in performing its functions or exercising its powers under this 
Act, the appeals committee must— (a) act independently; and (b) comply with the 
principles of natural justice”.238 This system of appeal is consistent with the principle of 
the Act to regulate psychoactive substances and the requirement that only psychoactive 
products that pose a low risk of harm should be approved.239 The PSAC is the body 
responsible for ensuring psychoactive products that pose only a low risk of harm are 
approved.240 Furthermore, the PSAC will also ensure such products are not subjected to 
undue conditions or recall orders. The PSAC is also responsible for reviewing decisions 
  
233  Section 88. 
234  Section 88(4). 
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made by the Authority in relation to licences that have been refused, revoked, subjected 
to a recall order, or unduly encumbered by conditions.241 This provides protection for the 
psychoactive substances industry, whereby the PSAC can ensure manufacturers and 
importers of good repute are able to obtain licences.  
 
The system does not allow decisions made by the Authority to be appealed by a third-
party. The Southern District Health Board recommended that s 45 be expanded to 
allow:242 
 
… individuals or organisations to challenge the decision of the Authority. Thus 
individuals or organisations that may have particular knowledge about the risk of harm to 
any individual may provide such information for consideration.  
 
However, the Health Select Committee did “not consider it desirable for third parties to 
be able to appeal decisions of the regulator”.243 It appears contrary to the purpose of the 
Act to prohibit third parties from bringing to the attention of the PSAC evidence that 
suggests that a product should not have obtained approval, or that a licence should not 
have been granted. The PSA is already inherently paternalistic, and it would be a 
justifiable limitation on the autonomy of manufacturers and importers to allow third-party 
individuals to appeal decisions made by the Authority in order to protect individual and 
public safety. 
M How are the Restrictions and Prohibitions on the Importation, Manufacture and 
Sale of Psychoactive Products Enforced? 
 
Section 76 provides for the appointment of enforcement officers. This provision has 
enabled officials to prosecute individuals who have committed offences under the 
PSA.244 In accordance with this objective, s 82 determines that psychoactive substances 
are subject to forfeiture if they are supplied or possessed in a manner that is considered to 
be an offence under the Act.245 Section 78 also permits any enforcement officer or 
constable to enter and search retail premises. Recently, a dairy in Hamilton was searched 
  
241  Section 45(1). 
242  Southern District Health Board “Submission to the Health Committee on the Psychoactive  
Substances Bill 2013” at [6]. 
243  Psychoactive Substances Bill (100-2) (commentary) at 4.  
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and “charged on one count of selling/supplying a non-approved psychoactive product and 
a second charge of possession for sale/supply of a non-approved psychoactive 
product”.246 The owners of the dairy now may face a fine of up to $50,000.247 This 
demonstrates that the provisions under the PSA are being utilised by officials to ensure 
compliance with the PSA. 
N Offences Relating to Psychoactive Substances that are not Approved Products  
 
Section 70(1) outlines the offences relating to non-approved psychoactive substances 
under the PSA: 
  
 A person commits an offence if the person, without reasonable excuse, -  
(a)   sells or supplies a psychoactive substance that is not an approved product  
to any person; or  
(b)   offers to sell or supply a psychoactive substance that is not an approved  
product to any person; or 
(c)   possesses a psychoactive substance that is not an approved product with  
the intent to sell or supply the psychoactive substance to any person 
 
Section 70(3) also establishes the penalties for this offence:  
 
 A person who commits an offence… is liable on conviction –  
(a) in the case of an individual, to a term of imprisonment not exceeding 2  
years: 
(b) in the case of a body corporate, to a fine not exceeding $500,000.  
 
The existence of this offence is of fundamental importance to the Act. Non-approved 
psychoactive substances may potentially pose the greatest risk of harm to individual 
consumers and society. These psychoactive substances are either substances which have 
not been considered by the Authority, or alternatively, have been considered by the 
Authority and deemed to pose more than a low risk of harm. Consequently, it is important 
to ensure that the penalties provide a sufficient level of deterrence to individuals and 
body corporates from providing such substances to individual consumers.  
  
246  Fairfax New Zealand News, above n 241.  
247  Psychoactive Substances Act, s 52. 
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O Should Personal Possession of a Psychoactive Substance be an Offence under the 
Psychoactive Substances Act? 
1 Unlawful possession of unapproved psychoactive substances  
 
It is an infringement offence, under s 71, for a person to have possession of a 
psychoactive substance that is not an approved product.248 The penalty for this offence is 
that the individual will be liable on conviction to pay a fine not exceeding $500. This will 
also allow officials to seize unapproved substances from individuals.249 However, the 
Whanganui Community Action Youth and Drugs organisation submitted that:250 
 
The [PSA] currently reverses the onus of proof so that the accused would have to prove 
the product they are carrying is either an approved product; not a “psychoactive 
substance”; or that they had a reasonable excuse for possessing the substance. The cost of 
establishing the nature of the substance will fall on them. 
 
This concern is a viable one. Section 72 of the PSA establishes that a constable may serve 
an infringement notice if he or she “has reasonable grounds to believe… an offence is 
being… committed”.251 It is problematic that individuals, who may often be part of a 
vulnerable population, will have to fund extensive testing on any substances they had on 
their person to prove their innocence. Because of the extensive costs of testing, it would 
be reasonable, in relation to the offence of personal possession, to instead impose this 
onus on the authorities to prove that the substance was an unapproved psychoactive 
substance.  
 
Furthermore, the Auckland Regional Meththanthetamine Working Group suggested that 
the offence for personal possession should be removed “provided the person in 
possession accurately identifies where the product was obtained”.252 This type of ouster 
clause for personal possession would allow authorities to better track retailers who are 
providing and selling unapproved psychoactive products. Consequently, such retailers 
  
248  Section 71.  
249  Ministry of Health Regulatory Impact Statement: New Regulatory Regime for Psychoactive  
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could then be charged under the PSA and prohibited from selling any psychoactive 
products in the future. This alternative would minimise the harm caused to other 
consumers visiting the same premises in an attempt to obtain unapproved psychoactive 
products.  
 
This paper suggests that imposing offences on individual consumers should be a last 
resort. Nevertheless, it also recognises that it is of fundamental importance that 
authorities are, firstly, able to confiscate such potentially harmful products and, secondly, 
able to dissuade individuals from using such unapproved products.  
2 Unlawful possession by minors of Psychoactive Products 
 
Section 48 states “a person under the age of 18 years commits an offence if the person 
buys or possesses any psychoactive substance, including an approved product”. The 
consequence for this offence is that an individual may be “liable on conviction to a fine 
not exceeding $500”. This provision addresses the social problem where “children as 
young as 14 are developing a petty crime habit to pay for their $500 a week habit”.253 
These age restrictions exist to protect minors, who are unable to make informed decisions 
in relation to psychoactive products, from the detrimental effects that may be caused by 
such products.  
 
Submissions were made to the Health Select Committee which suggested that the 
existence of an offence for personal possession of psychoactive products by individuals 
under the age of 18 years old would result in “young people having their future travel and 
employment options blighted through youthful foolishness”.254 Mr McClay responded to 
this concern by providing assurance that Parliament:255 
 
… carefully made sure no one will receive a criminal conviction simply by possessing one of 
these substances. The worst thing that can happen is an infringement notice similar to a 
speeding ticket. I am assured by police that even this would be a last resort. 
 
This assertion that only infringement notices will be imposed is reassuring and places less 
of an encumbrance on individual autonomy than home detention or imprisonment would. 
Mr McClay has also acknowledged this “will allow police to intervene and prevent harm 
  
253  Brook Sabin, above n 4.  
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to young people and harm from unapproved substances”.256 Nevertheless, it is 
problematic to consider that an Act created to protect the vulnerable may in reality inflict 
further harm. 
IX Conclusion 
The law, in its previous state, allowed unregulated psychoactive substances to cause 
substantial harm to individual health and society. This paper focussed on three case 
studies to determine the types of harms such substances may impose.  All three case 
studies demonstrated that psychoactive substances are able to impose severely 
detrimental harms on individual consumers and society.  
 
This paper then moved to consider the theoretical justifications for the paternalistic nature 
of the PSA. It concluded that the restrictions created under the PSA were justified. It is 
necessary for the state to impose limitations on the individual autonomy of consumers 
and the psychoactive substances industry in order to protect individuals, including 
minors, from the harms such products may cause, and the risk of substance dependence.  
 
This paper also established that the previous TCDN mechanism, which existed under the 
MoDA, was insufficient. This system imposed substantial financial costs on the 
government, allowed significant time delays, and was unable to keep up with the speed in 
which new psychoactive substances were reaching the public. Having determined that the 
previous method of controlling psychoactive substances was inadequate; this paper 
asserted that a new regulatory mechanism, such as the one provided by the PSA, was 
necessary.   
 
This paper concluded that the PSA was a great initiative and a step forward in the right 
direction. It was acknowledged in Part VIII that the regulatory scheme under the PSA 
would benefit from the creation of further restrictions on the autonomy of manufacturers, 
importers and retailers. Nevertheless, the PSA provides a strong legislative framework 
that will provide the state a great opportunity to remove the threat previously posed by 
psychoactive substances in New Zealand. In conclusion, it is proposed that the Act has 
numerous positive attributes and provides a well-designed safety mechanism that will 
minimise the risk of harm caused to individuals and society by psychoactive substances. 
 
 
  
256  At 11391. 
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X Appendix One: Abbreviations and Acronyms  
 
DHB    District Health Board 
BERL   Business and Economic Research Ltd 
GHB    Gamma-Hydroxybutyric Acid 
IPSEAC  Interim Psychoactive Substances Expert Advisory Committee 
MDPV   Methylenedioxypyrovalerone  
MoDA   Misuse of Drugs Act 1975 
NHSPB  Natural Health and Supplementary Products Bill 2013 
NZDF   New Zealand Drug Foundation  
NZPA   New Zealand Police Association  
NZPHDA  New Zealand Public Health and Disability Act 2000 
PSA   Psychoactive Substances Act 2013 
PSAC    Psychoactive Substances Appeal Committee 
PSEAC    Psychoactive Substances Expert Advisory Committee 
TCDN    Temporary Class Drug Notices  
The Authority   Psychoactive Substances Regulatory Authority   
 
